PURE BIOSCIENCE, INC. Form 8-K April 14, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 9, 2014

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction

001-14468 (Commission

33-0530289 (IRS Employer

of incorporation)

File Number) 1725 Gillespie Way

Identification No.)

Edgar Filing: PURE BIOSCIENCE, INC. - Form 8-K El Cajon, California 92020

(Address of principal executive offices, including zip code)

(619) 596-8600

(Registrant s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On April 9, 2014, Craig C. Culver, a member of the Board of Directors (the Board) of PURE Bioscience, Inc. (the Company) resigned from the Board, effectively immediately. Mr. Culver was also serving as Chairman of the Company s compensation committee. There are no disagreements between Mr. Culver and the Company relative to his resignation.

The Company issued a press release announcing the resignation of Mr. Culver from its Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished with this report:

Exhibit

No. Exhibit Description

99.1 Press Release issued by the Company on April 14, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 14, 2014

PURE BIOSCIENCE, INC.

By: /s/ Peter C. Wulff Peter C. Wulff,

Chief Financial Officer